ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

argenx, Halozyme Therapeutics and Takeda side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

argenx×Halozyme Therapeutics×Takeda×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

argenxHalozyme TherapeuticsTakeda
studies on the registry93421,754
open to participants now30186
phase 3 studies under way16144
reach primary completion within a year21047
programswith a study of their own in two years14none read25

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseargenxHalozyme TherapeuticsTakeda
Phase 1

argenx: 7 of its 14 programs at phase 1

  1. Adimanebart SC - formulation Aphase 1
  2. ARGX-124phase 1
  3. empasiprubart SC AIphase 1
  4. ARGX-109phase 1
  5. ARGX-213phase 1

and 2 more — sign in to see them all

50%
–

Takeda: 1 of its 25 programs at phase 1

  1. TAK-781phase 1
4%
Phase 2

argenx: 3 of its 14 programs at phase 2

  1. FB102phase 2
  2. Anti-MuSK Agonistic Monoclonal Antibody ARGX-119phase 2
  3. ARGX-121phase 2
21%
–

Takeda: 5 of its 25 programs at phase 2

  1. rusfertidephase 2
  2. Anti-CCR8 Antibody-drug Conjugate TAK-188phase 2
  3. Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505phase 2
  4. TAK-411phase 2
  5. TAK-951phase 2
20%
Phase 3

argenx: 2 of its 14 programs at phase 3

  1. empasiprubartphase 3
  2. adimanebartphase 3
14%
–

Takeda: 11 of its 25 programs at phase 3

  1. zasocitinibphase 3
  2. elriterceptphase 3
  3. mezagitamabphase 3
  4. TAK-360phase 3
  5. TAK-003phase 3

and 6 more — sign in to see them all

44%
Approved, new studies

argenx: 2 of its 14 programs at approved, new studies

  1. efgartigimod alfaapproved, new study
  2. hyaluronidase (human recombinant)approved, new study
14%
–

Takeda: 8 of its 25 programs at approved, new studies

  1. Immunoglobulins, Intravenousapproved, new study
  2. Brentuximab Vedotinapproved, new study
  3. Vinblastineapproved, new study
  4. Vortioxetineapproved, new study
  5. antihemophilic factor, human recombinantapproved, new study

and 3 more — sign in to see them all

32%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
argenx9 readouts · 1 phase 3

argenx, Nov ’26: 1 program whose next study reaches primary completion

  1. empasiprubartphase 3 · Nov 0 · NCT06284954

argenx, Dec ’26: 4 programs whose next study reaches primary completion

  1. adimanebartphase 3 · Dec 0 · NCT07673601
  2. Adimanebart SC - formulation Aphase 1 · Dec 0 · NCT07673601
  3. ARGX-124phase 1 · Dec 31 · NCT07377396
  4. FB102phase 2 · Dec 31 · NCT06905873
··

argenx, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. efgartigimod alfaapproved, new study · Mar 0 · NCT04833894
  2. empasiprubart SC AIphase 1 · Mar 0 · NCT07612020
  3. hyaluronidase (human recombinant)approved, new study · Mar 0 · NCT06655155
····

argenx, Aug ’27: 1 program whose next study reaches primary completion

  1. Anti-MuSK Agonistic Monoclonal Antibody ARGX-119phase 2 · Aug 24 · NCT06436742
··
Halozyme Therapeutics0 readouts · 0 phase 3············
Takeda7 readouts · 4 phase 3

Takeda, Nov ’26: 1 program whose next study reaches primary completion

  1. TAK-360phase 3 · Nov 30 · NCT06952699

Takeda, Dec ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. oveporextonphase 3 · Dec 17 · NCT07363720
·

Takeda, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zasocitinibphase 3 · Feb 5 · NCT07244263
  2. teduglutidephase 3 · Feb 10 · NCT06973304

Takeda, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. apadamtase alfaphase 3 · Mar 16 · NCT04683003

Takeda, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. TAK-003phase 3 · Apr 14 · NCT06579755
·····

Takeda, Oct ’27: 1 program whose next study reaches primary completion

  1. rusfertidephase 2 · Oct 28 · NCT07648030
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

argenx

New programs 0

None

Reached a new phase 0

None

Study stopped 1

Primary completion later 2

Halozyme Therapeutics

No programs read for this company.

Takeda

New programs 1

  • TAK-664approved, new study · first study · Aug 26 · Primary Immunodeficiency Diseases

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 6 in all. A program counts in each condition its studies name most.

ConditionargenxHalozyme TherapeuticsTakeda
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating2 of 3 · compare here

argenx in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 2 programs

  1. empasiprubartphase 3
  2. efgartigimod alfaapproved, new study

Their studies: argenx’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

–

Takeda in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating: 4 programs

  1. TAK-411phase 2
  2. Immunoglobulins, Intravenousapproved, new study
  3. Hyaluronoglucosaminidaseapproved, new study
  4. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Polyradiculoneuropathy, Chronic Inflammatory Demyelinating in search

Primary Immunodeficiency Diseases2 of 3 · compare here

argenx in Primary Immunodeficiency Diseases: 1 program

  1. hyaluronidase (human recombinant)approved, new study

Their studies: argenx’s studies of Primary Immunodeficiency Diseases in search

–

Takeda in Primary Immunodeficiency Diseases: 4 programs

  1. Immunoglobulins, Intravenousapproved, new study
  2. TAK-664approved, new study
  3. Hyaluronoglucosaminidaseapproved, new study
  4. Immunoglobulin Gapproved, new study

Their studies: Takeda’s studies of Primary Immunodeficiency Diseases in search

Myasthenia Gravis2 of 3 · compare here

argenx in Myasthenia Gravis: 3 programs

  1. empasiprubartphase 3
  2. efgartigimod alfaapproved, new study
  3. hyaluronidase (human recombinant)approved, new study

Their studies: argenx’s studies of Myasthenia Gravis in search

–

Takeda in Myasthenia Gravis: 1 program

  1. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Myasthenia Gravis in search

Purpura, Thrombocytopenic, Idiopathic2 of 3 · compare here

argenx in Purpura, Thrombocytopenic, Idiopathic: 1 program

  1. efgartigimod alfaapproved, new study

Their studies: argenx’s studies of Purpura, Thrombocytopenic, Idiopathic in search

–

Takeda in Purpura, Thrombocytopenic, Idiopathic: 2 programs

  1. mezagitamabphase 3
  2. Immunoglobulins, Intravenousapproved, new study

Their studies: Takeda’s studies of Purpura, Thrombocytopenic, Idiopathic in search

Multiple Myeloma2 of 3 · compare here

argenx in Multiple Myeloma: 1 program

  1. hyaluronidase (human recombinant)approved, new study

Their studies: argenx’s studies of Multiple Myeloma in search

–

Takeda in Multiple Myeloma: 1 program

  1. mezagitamabphase 3

Their studies: Takeda’s studies of Multiple Myeloma in search

Vitiligo2 of 3 · compare here

argenx in Vitiligo: 1 program

  1. FB102phase 2

Their studies: argenx’s studies of Vitiligo in search

–

Takeda in Vitiligo: 1 program

  1. zasocitinibphase 3

Their studies: Takeda’s studies of Vitiligo in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: argenx 1 of 14 · Halozyme Therapeutics 0 of 0 · Takeda 12 of 25 programs (13 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.